In order to empower patients as partners in their healthcare decisions, there is an identified need for value tools that provide enough information to help them make decisions regarding their cancer care journey. NCCN convened a multistakeholder working group to identify the gaps and needs of current value tools and develop a set of findings and recommendations for the evolution of value tools for patients. The findings and recommendations of the working group were then presented at the Value Tools for Patients in Cancer Care Patient Advocacy Summit in December 2016, and multistakeholder roundtable panel discussions explored these findings and recommendations along with additional items. This article encapsulates the discussion from the NCCN Working Group meetings and the NCCN Patient Advocacy Summit, including identified gaps and needs in defining value in cancer care, identified principles and parameters of value tools for patients in cancer care, and consensus statements and recommendations offered by the NCCN Working Group.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.6004/jnccn.2017.0118 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Adapting the MUSIQ Calculator for Practice Facilitators to Evaluate Primary Care Clinic Performance in a Colorectal Cancer Screening Quality Improvement Project.
J Prim Care Community Health
March 2025
West Virginia University School of Medicine, Morgantown, WV, USA.
The Model for Understanding Success in Quality (MUSIQ) is a framework designed to understand the contextual factors that can influence healthcare quality improvement (QI) initiative implementation. The MUSIQ calculator was originally developed to help clinics identify contextual factors that may affect QI success. This retrospective study adapted the MUSIQ calculator to serve as an evaluative tool for practice facilitators engaged in a colorectal cancer screening initiative.
View Article and Find Full Text PDFThe search for a TNBC vaccine: the guardian vaccine.
Cancer Biol Ther
December 2025
School of Pharmacy, Queen's University Belfast, Belfast, UK.
Nearly 20 million people are diagnosed with cancer each year with breast cancer being the most common among women. Triple negative breast cancer (TNBC), defined by its no/low expression of ER and PR and lack of amplification of HER2, makes up 15-20% of all breast cancer cases. While patients overall have a higher response to chemotherapy, this subgroup is associated with the lowest survival rate indicating significant clinical and molecular heterogeneity demanding alternate treatment options.
View Article and Find Full Text PDFPrinciples of optimal multidisciplinary management of prostate cancer in clinical practice.
Cardiooncology
March 2025
Department of Medicine and Population Health Research Institute, McMaster University, Hamilton, Canada.
Advances in the diagnosis and management of prostate cancer have significantly changed the disease landscape. While benefiting from better oncological outcomes, patients are now experiencing higher rates of non-cancer comorbidities, including cardiovascular disease. The increasing impact of cardiovascular disease in those with prostate cancer led to the expanding role of cardio-oncology professionals in enhancing the multidisciplinary care of these patients.
View Article and Find Full Text PDF'I was eager to do anything I could to improve the situation': a qualitative study of patients' experiences and views of prehabilitation for ovarian cancer surgery.
BMC Womens Health
March 2025
Nursing Directorate, Imperial College Healthcare NHS Trust, Charing Cross Hospital, Fulham Palace Road, London, UK.
Background: Prehabilitation has shown promise in improving post-operative outcomes for several solid tumour groups. However, prehabilitation programmes are not widely established. Patients with advanced ovarian cancer experience life changing debulking surgery and could benefit from prehabilitation.
View Article and Find Full Text PDFRisk prediction and early intervention strategies for persistent SARS-CoV-2 infection in patients with non-Hodgkin lymphoma: a retrospective cohort study.
BMC Pulm Med
March 2025
Department of Pulmonary and Critical Care Medicine, Aerospace Center Hospital, Beijing, 100049, China.
Background: Patients with non-Hodgkin lymphoma (NHL) face heightened mortality and accelerated disease progression when persistently infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This critical situation underscores the urgent need to identify risk factors and establish early intervention strategies tailored to this vulnerable population. The primary aim of this study was to investigate the risk factors associated with persistent SARS-CoV-2 infection in NHL patients during the COVID-19 pandemic.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!